DRI Healthcare Trust Announces Appointment of Annalisa King to Board of Trustees and as Chair of the Audit Committee
– Adds extensive expertise in audit, risk and financial strategy –
TORONTO, June 9, 2025 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced Annalisa King has been appointed as an independent member and chair of the audit committee of the Trust's board of trustees effective immediately.
Ms. King is the chair of the board for Vancouver Airport Authority and an experienced corporate director serving on three TSX public company boards. She is the chair of the audit committee at both Saputo Inc. and The North West Company Inc. and is the chair of the compensation committee at First Capital Real Estate Investment Trust. In addition to her board work, Ms. King is the National Academic Director of the Board Oversight of Strategy course at the Institute of Corporate Directors.
Ms. King was the Senior Vice President and Chief Financial Officer of Best Buy Canada Ltd. from 2008 to 2016, where, in addition to her finance responsibilities, she also led the information technology, ecommerce technology, cyber security, legal and real estate functions.
Recognized in 2012 as the British Columbia CFO of the Year by Business in Vancouver, Ms. King is one of Canada's most respected senior business executives. She received the award for Significant Board Contribution by the Association of Women in Finance in 2019 and was inducted into the Canada's Most Powerful Women: Top 100 Hall of Fame™ in 2010. Her dedication to leadership has earned her a reputation as a dynamic business thought-leader in the areas of corporate finance and business transformation.
"On behalf of the Trust and my fellow trustees, I am very pleased to welcome Annalisa King to the board," said Gary Collins, the Trust's Chief Executive Officer and Chairman. "Annalisa's extensive audit, risk and financial experience provides a strong addition to the board. I look forward to working with her on behalf of our unitholders."
With the addition of Ms. King, the Trust's board is now made up of eight members with backgrounds in the areas of pharmaceuticals, government, business, finance, law, cybersecurity and governance, all critical to the continued growth and prosperity of the Trust.
The Trust is managed by DRI Capital Inc., a pioneer in global pharmaceutical royalty monetization. Since its initial public offering in 2021, the Trust has deployed more than $1.0 billion, acquiring more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. The Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". To learn more, visit drihealthcare.com or follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
MedX Announces Final Closing of Non-Brokered Private Placement
MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ('Unit'). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant ( s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants (' Agent's Warrant(s) ') (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Cision Canada
an hour ago
- Cision Canada
ANNUAL GENERAL MEETING
VANCOUVER, BC, June 9, 2025 /CNW/ - (TSX: AOI) (Nasdaq-Stockholm: AOI) – Meren Energy Inc. ("Meren" or the "Company") confirms that its Annual General Meeting of Shareholders will be held on Thursday, June 12, 2025 at 09:00 am (Pacific Time) at Bennett Jones LLP Fraser Boardroom, Park Place, 666 Burrard Street, Suite 2500, Vancouver V6C 2X8. View PDF version The purpose of the Meeting is as follows: View PDF To receive the consolidated audited financial statements and accompanying management's discussion and analysis of the Company for the year ended December 31, 2024, together with the report of the auditors; To appoint PricewaterhouseCoopers LLP as auditors of the Company to hold office until the next Annual General Meeting, at a remuneration to be fixed by the directors of the Company; To consider and, if deemed advisable, to approve an advisory resolution to accept the Company's approach to executive compensation; and To elect directors to hold office for the ensuing year. The record date for the Annual General Meeting of Shareholders is April 24, 2025. The Notice of Meeting, Management Information Circular, and related meeting materials are available under the Company's profile on SEDAR at and on the Company's website at About Meren Meren is a full-cycle Independent upstream oil and gas company with interests offshore Nigeria, Namibia, South Africa and Equatorial Guinea. Its main assets are producing and development assets in deepwater Nigeria operated by Majors. The Company holds a leading position in the Orange Basin including its effective interest in the Venus light oil project, offshore Namibia, and its direct interest in Block 3B/4B, offshore South Africa. Additional Information This information was submitted for publication, through the agency of the contact persons set out above, at 6:30 p.m. EDT on June 9, 2025. Forward Looking Information Certain statements and information contained herein constitute "forward-looking information" (within the meaning of applicable Canadian securities legislation). Such statements and information (together, "forward-looking statements") relate to future events or the Company's future performance, business prospects or opportunities. All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect, "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions) are not statements of historical fact and may be "forward looking statements". SOURCE Meren Energy Inc.
Cision Canada
an hour ago
- Cision Canada
SIGNIFICANT GOLD ASSAYS REPORTED IN ROCK SAMPLES FROM BARRANCO GOLD'S KING PROJECT
VANCOUVER, BC, June 9, 2025 /CNW/ - Barranco Gold Mining Corp. ("Barranco" or the "Company") (CSE: BAR) is pleased to report results from its initial rock sampling program conducted at the 100%-owned King Property, located approximately 50 km south of Merritt, British Columbia, in the Quesnel Terrane. The King Property consists of nine contiguous mineral claims covering 3,456 hectares. The Company's field team collected a total of 31 rock samples (grab and chip) from outcrops, float material, and altered zones across structurally controlled targets identified within the Main and Central Grid areas. Assays have returned encouraging gold values, with the highest result at 1.83 g/t gold, indicating a promising mineralized system. Rock Sampling Highlights • 31 rock samples collected Sample 906575 (grab): 1.83 g/t Au, 97 ppm cu, 131 ppm Zn Sample 440683 (70 cm chip): 1.39 g/t Au, 118 ppm Cu Additional samples showed elevated arsenic, antimony, zinc, and lead Coordinates were recorded using handheld GPS units and archived in the GIS database Assays performed at Activation Laboratories (ActLabs), Ancaster, Ontario, using fire assay (FA-AA) and ICP-OES Geological Context The King Property is underlain by multi-phase intrusive rocks of the Osprey Lake and Pennask Batholiths, intersected by quartz-feldspar porphyry dykes of the Otter Intrusion. Mineralization occurs along NE- and NW-trending fault zones and is interpreted to reflect a porphyry-epithermal hybrid system similar to other known deposits in southern British Columbia, such as Copper Mountain and Brenda Mine. Quality Assurance and Quality Control (QA/QC) Barranco followed a robust QA/QC protocol. Sample batches included blanks, field duplicates, and certified reference materials. All data was reviewed internally to verify laboratory accuracy. Sampling was conducted under supervision of experienced geological staff. Qualified Person The technical content of this press release has been reviewed and approved by Derrick Strickland, a Qualified Person as defined under NI 43-101. Mr. Strickland is independent of the Company and authored the NI 43-101 Technical Report on the King Property dated November 23, 2023. Cautionary Statements Grab samples are selective and may not be representative of the overall mineralization on the property. Geochemical and geophysical surveys are preliminary and do not confirm the presence of economically recoverable mineral resources Next Steps Barranco is currently integrating sampling results into a 3D geological model to prioritize targets for Phase 2 exploration. Upcoming activities are expected to include: Expansion of soil grids • IP geophysics Detailed structural mapping and trenching Drill targeting in late 2025 The Canadian Securities Exchange has not in any way passed upon the merits of the matters referenced herein and has neither approved nor disapproved the contents of this news release. Forward-Looking Statement: This news release may contain statements that constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding, among other things, expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects expectations of the Company's management, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; and compliance with extensive government regulation. This forward- looking information may be affected by risks and uncertainties in the business of the Company and market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward- looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
